US6402681083 - NKTR - 165417 (XNAS)
NEKTAR THERAPEUTICSCS Aktie
1,24 USD
Aktuelle Kurse von NEKTAR THERAPEUTICSCS
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
NKTR
|
USD
|
20.09.2024 00:52
|
1,24 USD
| 1,26 USD | -1,59 % |
London |
0UNL.L
|
USD
|
19.09.2024 16:10
|
1,28 USD
| 1,26 USD | 1,63 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -4,62 % | -1,98 % | 8,77 % | 38,18 % | 83,16 % | -93,87 % |
Firmenprofil zu NEKTAR THERAPEUTICSCS Aktie
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Investierte Fonds
Folgende Fonds haben in NEKTAR THERAPEUTICSCS investiert:
Fonds | Vol. in Mio 95,85 | Anteil (%) 0,22 % |
Unternehmensdaten zur NEKTAR THERAPEUTICSCS Aktie
Name NEKTAR THERAPEUTICSCS
Firma Nektar Therapeutics
Symbol NKTR
Website https://www.nektar.com
Heimatbörse
NASDAQ
WKN 165417
ISIN US6402681083
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Howard W. Robin
Marktkapitalisierung 236 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 455 Mission Bay Boulevard South, 94158 San Francisco
IPO Datum 1994-05-03
Aktien-Splits
Datum | Split |
---|---|
23.08.2000 | 2:1 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | ITH.F |
London | 0UNL.L |
NASDAQ | NKTR |
Weitere Aktien
Investoren die NEKTAR THERAPEUTICSCS halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024